MSD Animal Health To Present Important Data at 6th Asian Pig Veterinary Society Congress in Vietnam

Porcine Reproductive and Respiratory Syndrome (PRRS) to be Focus of Data Presentations 

SUMMIT, NEW JERSEY 20 September 2013 — MSD Animal Health (known as Merck Animal Health in the USA and Canada) announced today that data related to its swine products and product-related services will be presented at the 6th Asian Pig Veterinary Society (APVS) Congress 23 September – 25 September, 2013 in Ho Chi Minh City, Vietnam. Attendees will be introduced to new data from Europe and Asia supporting the company’s Porcilis PCV and Porcilis PRRS vaccines, covering various aspects on immunology and efficacy.

“The APVS Congress provides the ideal location to highlight key data related to the deadliest viruses that cause significant losses to the pig industry,” states Rob Barclay, Vice President, Asia Pacific MSD Animal Health. “Maintaining a healthy herd is vital to the Asian pig industry and we are committed to working with farmers to ensure the health and well-being of their animals.”

Abstracts selected for oral and poster presentations represent advances in swine vaccination and herd health, as follows:

Oral Presentations

  • Porcine circovirus type 2 diagnostic laboratory trends: relationship between year and production phase (Oral P284)
  • Virological and production evaluation of Circumvent® PCV M administered during and early field infection (Oral P285)
  • Comparison of One- And Two-Dose Vaccines Against Porcine Circovirus Type 2 in Piglets (Oral P302)
  • The Efficacy of A Type 1 PRRS Vaccine (Based on the Dv Strain) Tested in Piglets Under Field Conditions in Japan (Oral P243)
  • Safety and Efficacy of Porcilis® PRRS Vaccine in Vietnam (Oral P239)
  • PRRS stabilisation in a high pig density area, by intradermal mass-vaccination (Porcilis® PRRS) and strict biosecurity measures (Oral P269)
  • Synchronization of estrus and ovulation by an altrenogest/buserelin treatment in gilts results in good fertility and prolificacy following a single fixed time AI. (Oral P175)

Poster Presentations

  • A safe and efficacious MLV vaccine can contribute to the control and eradication of PRRSV (Poster P169)
  • Benefits of novel intradermal vaccination with a modified live vaccine against PRRS (Poster P170)
  • Effect of MLV PRRSV (Porcilis PRRS) Vaccination in the Control of an Acute PRRS Field Virus Infection in a Philippine Commercial Swine Farm (Poster P167)
  • Presence of Both PRRS Type 1 and Type 2 Antibodies in Philippine Commercial Swine Farms (Poster P166)
  • Comparison of Interleukin-10 Levels in Pigs Vaccinated with Modified Live PRRSV Vaccines of Type 1 and Type II Genotypes (Poster P119)
  • Reduction of mortality and culling by the use of Porcilis® PCV and/or Porcilis® Glaesser (Poster P174)
  • Laboratory studies on Circumvent® PCV M: combination Mycoplasma Hyopneumoniae and porcine circovirus type 2 vaccine (Poster P287)
  • Field evaluation of Circumvent PCV M: combination Mycoplasma Hyopneumoniae and porcine circovirus type 2 vaccine (Poster P286)
  • Diagnostic laboratory survey of porcine circovirus type 2 and Mycoplasma Hyopneumoniae maternally-derived antibodies (Poster P288)
  • Altering the PCV2 vaccination program as a means of improving productivity (Poster R27)
  • A single fixed time insemination following ovulation induction by buserelin injection at 86 hours after weaning in sows generates good fertility and prolificacy (Poster P177)
  • Evaluation Of The Benefits of AIAO/Batch Management System Implementation in Philippine Swine Farms (Poster P168)

Monday, September 23, 16:45– 17:45 Room: Crystal 3 – “PRRS – New Developments Impacting Vaccination in Asia”
During this seminar, attendees will have the opportunity to learn new developments in PRRS infection and control mechanisms. Trial results specific to Vietnam, Thailand and Japan will be presented. Presentations will be given by Dr. Paolo Martelli, DVM, Professor of Internal Medicine (Veterinary Clinical Medicine) at Parma University, Department of Veterinary Sciences and Dr. Rika Jolie, Global Technical Director, MSD Animal Health.

In addition to the presentation of selected abstracts, MSD Animal Health will host a satellite symposium for industry professionals attending the Congress.

About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (